The socioeconomic consequences of multiple sclerosis: A controlled national study

European Neuropsychopharmacology

Volumn 22, Issue 1, 2012, Pages 36-43

  Jennum, Poul ^a   Wanscher, Benedikte ^a   Frederiksen, Jette ^b   Kjellberg, Jakob ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Dansk Sundhedsinstitut   (Denmark)

Author keywords

Controlled trial; Costs; Economy; Multiple sclerosis; Social

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENMARK; DRUG COST; DRUG USE; EMPLOYMENT; FEMALE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MONEY; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PRODUCTIVITY; SOCIOECONOMICS;

ADULT; AGED; AGED, 80 AND OVER; COST OF ILLNESS; DENMARK; EMPLOYMENT; FEMALE; HEALTH CARE COSTS; HEALTH EXPENDITURES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 84155165587     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.05.001     Document Type: Article

References (24)

1. Bryant J., Clegg A., Milne R. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast. BMJ 2000, 320:1474-1475.
2. Clerico M., Contessa G., Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert. Opin. Biol. Ther. 2007, 7:535-542.
3. Efron B., Tibshirani R.J. An Introduction to the Bootstrap 2008, 1993, Chapman & Hall.
4. Fergusson D., Hutton B., Sharma M., Tinmouth A., Wilson K., Cameron D.W., Hebert P.C. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005, 45(10):1640-1657.
5. Grima D.T., Torrance G.W., Francis G., Rice G., Rosner A.J., Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult. Scler. 2000, 6:91-98.
6. Grudzinski A.N., Hakim Z., Cox E.R., Bootman J.L. The economics of multiple sclerosis. Distribution of costs and relationship to disease severity. PharmacoEconomics 1999, 15:229-240.
7. Iskedjian M., Walker J.H., Gray T., Vicente C., Einarson T.R., Gehshan A. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult. Scler. 2005, 11:542-551.
8. Kobelt G. Economic evidence in multiple sclerosis: a review. Eur. J. Health Econ. 2004, 5(Suppl. 1):S54-S62.
9. Kobelt G., Pugliatti M. Cost of multiple sclerosis in Europe. Eur. J. Neurol. 2005, 12(Suppl 1):63-67.
10. Kobelt G., Berg J., Atherly D., Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006, 66:1696-1702.
11. Kobelt G., Berg J., Lindgren P., Fredrikson S., Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 2006, 77:918-926.
12. Kobelt G., Berg J., Lindgren P., Jonsson B. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur. J. Health Econ. 2006, 7(Suppl. 2):S5-13.
13. Kunze A.M., Gunderson B.W., Gleason P.P., Heaton A.H., Johnson S.V. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs - pharmacy and medical benefit spending from 2004 through 2007. J. Manag. Care Pharm. 2007, 13:799-806.
14. Lazzaro C., Bianchi C., Peracino L., Zacchetti P., Uccelli A. Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol. Sci. 2009, 30:21-31.
15. Marrie R.A., Horwitz R., Cutter G., Tyry T., Campagnolo D., Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult. Scler. 2009, 15:385-392.
16. Miltenburger C., Kobelt G. Quality of life and cost of multiple sclerosis. Clin. Neurol. Neurosurg. 2002, 104:272-275.
17. Morales-Gonzales J.M., Benito-Leon J., Rivera-Navarro J., Mitchell A.J. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult. Scler. 2004, 10:47-54.
18. O'Brien J.A., Ward A.J., Patrick A.R., Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC. Health Serv. Res. 2003, 3:17.
19. Orlewska E., Mierzejewski P., Zaborski J., Kruszewska J., Wicha W., Fryze W., Drozdowski W., Skibicka I., Mirowska-Guzel D., Czlonkowski A., Czlonkowska A. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur. J. Neurol. 2005, 12:31-39.
20. Parkin D., McNamee P., Jacoby A., Miller P., Thomas S., Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol.Assess. 1998, 2. iii-54.
21. Parkin D., Jacoby A., McNamee P., Miller P., Thomas S., Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J. Neurol. Neurosurg. Psychiatry 2000, 68:144-149.
22. Pfleger C.C., Flachs E.M., Koch-Henriksen N. Social consequences of multiple sclerosis (1): early pension and temporary unemployment - a historical prospective cohort study. Mult. Scler. 2010, 16:121-126.
23. Robson L.S., Bain C., Beck S., Guthrie S., Coyte P.C., O'Connor P. Cost analysis of methylprednisolone treatment of multiple sclerosis patients. Can. J. Neurol. Sci. 1998, 25:222-229.
24. Vedula S.S., Brodney-Folse S., Gal R.L., Beck R. Corticosteroids for treating optic neuritis. Cochrane.Database.Syst.Rev. 2007, 1. CD001430.